AngII, a key component of the RAS, has been implicated in the progression of NAFLD, with AngII type 1 receptor blockers (ARB) showing considerable therapeutic effects in patients with NAFLD/NASH (Nabeshima et al., 2009; Matthew Morris et al., 2013). This evidence concerns the gene AGT and metabolic dysfunction-associated steatotic liver disease.